Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer

Cancer Science

Volumn 101, Issue 1, 2010, Pages 188-195

  Yamada, Kazuhiko ^a   Nakao, Masao ^a   Fukuyama, Chikara ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Sekine, Ikuo ^a   Kunitoh, Hideo ^a   Ohe, Yuichiro ^a   Ohki, Emiko ^b   Hashimoto, Junichi ^b   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; CARBOPLATIN; CHLORPHENIRAMINE; DEXAMETHASONE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INJECTION SITE REACTION; JAPANESE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALAISE; MALE; MONOCYTOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PACLITAXEL; TOLL-LIKE RECEPTOR 9;

EID: 71849087609     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01361.x     Document Type: Article

References (25)

1. Okamoto I, Moriyama E, Fujii S. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2005, 35:188-94.
2. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest 2006, 130:1211-9.
3. Pfister DG, Johnson DH, Azzoli CG. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-53.
4. Grossi F, Aita M, Follador A. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007, 12:451-64.
5. Schiller JH, Harrington D, Belani CP. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-8.
6. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-95.
7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
8. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-76.
9. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007, 117:1184-94.
10. Krieg AM, Efler SM, Wittpoth M. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004, 27:460-71.
11. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008, 27:161-7.
12. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-84.
13. Weeratna RD, Bourne LL, Sullivan SM. Combination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metastatic Lewis Lung Carcinoma (LLC). J Clin Oncol 2004, 22(Suppl):699. Abstract 7346
14. Kim Y, Girardi M, McAuley S, Schmalbach T. Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CpG immunomodulator (CPG 7909), a phase I study. J Clin Oncol 2004, 22(14 Suppl):580. Abstract 6600
15. Pashenkov M, Goess G, Wagner C. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006, 24:5716-24.
16. Thompson JA, Kuzel T, Bukowski R. Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC). J Clin Oncol 2004, 22(14 Suppl):416. Abstract 4644
17. Manegold C, Gravenor D, Woytowitz D. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3979-86.
18. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-16.
19. Ohe Y, Ohashi Y, Kubota K. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-23.
20. Scagliotti GV, De Marinis F, Rinaldi M. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-91.
21. Gandara DR, Ohe Y, Kubota K. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): a model for prospective comparison of cooperative group trials. J Clin Oncol 2004, 22(Suppl). Abstract 7007
22. Smit EF, van Meerbeeck JP, Lianes P. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003, 21:3909-17.
23. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997, 8:207-19.
24. Hirsh V, Boyer M, Rosell R. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) [oral presentation]. J Clin Oncol 2008, 26(Suppl):428s. Abstract 8016
25. Manegold C, Thatcher N, Benner RJ. Randomized phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) [oral presentation]. J Clin Oncol 2008, 26(Suppl):428s. Abstract 8017